CompoAtlas

STACKER2 EUROPE - STACKER 4 POWDER Fruit Punch

Food supplement declared in France, decision dated 15 July 2026

STACKER2 EUROPE - STACKER 4 POWDER Fruit Punch (STACKER2 EUROPE) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 2 rules of use apply to its ingredients (limits and warnings).

Brand
STACKER2 EUROPE
Food business operator placing the product on the market
Stacker2 Europe B.V.
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Poudre
Daily dose
1,5 g (1 cuillère doseuse) par jour
Intended populations
Hommes et femmes de 18 ans et plus
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Femmes enceintes, Insuffisance rénale, Problèmes cardiaques, Sous traitement antihypertenseur, Sous traitement pour la thyroïde, Ulcère (estomac ou duodenum)
Flavourings
Fruit Punch

Declaration 370924, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Camellia sinensis (L.) KuntzeFeuilleExtrait sec hydroalcoolique50 mg
Ilex paraguariensis A. St.-Hil.FeuilleExtrait sec aqueux35 mg
Paullinia cupana KunthGraineExtrait sec hydroalcoolique25 mg
Capsicum annuum L.FruitExtrait sec hydroalcoolique10 mg
Cola acuminata (P.Beauv.) Schott et Endl.GraineExtrait sec aqueux4 mg
Eleutherococcus senticosus (Rupr. et Maxim.) MaximRacineExtrait sec hydroalcoolique2 mg

Substances

NamePer day
caféine160 mg

Additives

E955, E160a, E330

Other ingredients

poudre de betterave

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Ne pas dépasser la dose journalière recommandée. Les compléments alimentaires ne doivent pas se substituer à une alimentation variée et équilibrée et à un mode de vie sain. Ne pas laisser à la portée des jeunes enfants. Ne pas consommer une quantité journalière de 800 mg ou plus d'épigallocatéchine-3-gallate (EGCG). Ne doit pas être consommé si vous prenez le même jour d'autres produits contenant du thé vert. Ne doit pas être consommé par les femmes enceintes ou allaitantes et par les enfants de moins de 18 ans. Ne doit pas étre consommé à jeun. Déconseillé en cas de troubles ou d'insuffisance cardiaque ou rénale œdémateuses, d'ulcère gastro-duodénal, d'hypertension artérielle, ou d'hyperthyroidie. En cas de traitements médicamenteux, demander conseil à un professionnel de santé.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Capsicum annuum L.
    Read the warning, when it applies and the studies cited

    CAYENNE - CAPSICUM ANNUUM Oral

    Cautions and warnings

    Condition of application: All products.

    Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: Digestion; Peripheral circulation.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 27 March 2026

    CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical

    Cautions and warnings

    Condition of application: All products.

    For external use only (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 27 March 2026

  • Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
    Read the warning, when it applies and the studies cited

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Route of administration: Oral (ESCOP 2003; Bradley 1992)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 October 2025

  • caféine
    Read the warning, when it applies and the studies cited

    CAFFEINE

    Route of administration: Oral (Higdon and Frei 2006)

    Cautions and warnings

    Applies to products providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Applies to products providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    8 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Applies to products providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    7 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Applies to products providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Condition of application: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : STACKER2 EUROPE

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line